1	Association of multidrug-resistant bacteria and clinical outcomes in patients with
2	infected diabetic foot in a Peruvian Hospital: A retrospective cohort analysis
3	
4	Authors
5	Marlon Yovera-Aldana ^{1*} , Paola Sifuentes-Hermenegildo ^{2,3} , Martha Sofia Cervera-Ocaña ⁴ ,
6	Edward Mezones-Holguin ^{5,6}
7	
8	Filiations
9	¹ Grupo de Investigación de Neurociencias, Efectividadad clínica y Salud Pública,
10	Universidad Científica del Sur, Lima, Peru.
11	² Servicio de Endocrinología, Departamento de Medicina, Hospital María Auxiliadora, Lima,
12	Peru.
13	³ Red de Eficacia Clínica y Sanitaria, Lima, Perú.
14	⁴ Facultad de Ciencias Médicas, Universidad César Vallejo. Trujillo, Peru.
15	⁵ Centro de Estudios Económicos y Sociales en Salud, Universidad San Ignacio de Loyola,
16	Lima, Peru.
17	⁶ Soluciones de Epi-gnosis. Piura, Peru.
18	
19	Corresponding author
20	E-mail: myovera@cientifica.edu.pe (MYA)

21 ABSTRACT

22

23 **Objective:** To evaluate the association of multidrug-resistant bacteria (MDRB) and adverse

24 clinical outcomes in patients with infected diabetic foot (IDF) in a Peruvian hospital.

Materials and Methods: This retrospective cohort study evaluated patients treated in the Diabetic Foot Unit of a General Hospital in Lima, Peru. MDRB was based on resistance to more than two pharmacological groups across six clinically significant genera. The primary outcome was death due to complications of the IDF and/or major amputation. Other outcomes included minor amputation, hospitalization, and a hospital stay longer than 14 days. Relative risks were estimated using Poisson regression for all outcomes.

Results: The study included 192 IDF patients with a mean age of 59.9 years; 74% were males. A total of 80.8% exhibited MDRB. The primary outcome had an incidence rate of 23.2% and 5.4% in patients with and without MDRB, respectively (p = 0.01). After adjusting for sex, age, bone involvement, severe infection, ischemia, diabetes duration, and glycosylated hemoglobin, MDRB showed no association with the primary outcome (RR 3.29; 95% CI, 0.77 - 13.9), but did with hospitalization longer than 14 days (RR 1.43; 95% CI, 1.04 - 1.98).

38 Conclusions: Our study found no association between MDRB and increased mortality and/or 39 major amputation but did find a correlation with prolonged hospitalization. The high 40 proportion of MDRB could limit the demonstration of the relationship. It is urgent to apply 41 continuous evaluation of bacterial resistance, implement a rational plan for antibiotic use, 42 and maintain biosafety to confront this threat.

43

44 Keywords: Diabetic foot; Bacterial infections; Drug-resistant, Multiple, Bacterial;
45 Amputation, surgical; Cohort studies; Peru

46 Introduction

47

Infected Diabetic Foot (IDF) is one of the leading causes of hospitalization in diabetic foot units, with 15-20% of cases requiring major amputation[1,2]. In Peru, it accounts for 18.9% of diabetes-related hospital admissions, and 61% of these cases develop sepsis[3]. Treatment costs are five times higher for patients who develop this complication, which impacts the healthcare system and patients' quality of life, particularly in developing countries[4]. Given the magnitude and significant impact of this complication, effective and personalized treatment is needed.

55

Antibiotic resistance poses a threat to the successful treatment of IDF[5]. The prevalence of 56 Multidrug-Resistant Bacteria (MDRB) varies from 14% to 66%[6,7], depending on the 57 58 country studied. MDRB is associated with protracted recovery, increased need for surgical procedures, prolonged hospital stays, and higher treatment costs[8]. Additionally, it results 59 in increased protein-nutritional requirements, higher oxygen consumption, disturbed 60 glycemic control, and reduced hemoglobin levels[9]. As these are polymicrobial infections, 61 the use of broad-spectrum antibiotics is recommended for severe infections, subsequently 62 63 deescalating according to the antibiogram[10]. For a proper IDF approach, it is mandatory to determine the bacteriological resistance profile at each healthcare facility and to devise a 64 treatment algorithm based on those results[11]. 65

66

The influence of MDRB on the clinical outcomes of IDF is not well understood[7], with scant research conducted in Latin America on the subject[3]. Factors such as inappropriate antibiotic selection due to the lack of an antibiogram, reduced antibiotic concentration in tissues caused by peripheral ischemia, and colonization by resistant strains due to frequent

hospitalizations or prolonged treatments have been documented[12]. Furthermore, at the
local level, only 30% of outpatient individuals have an HbA1c level below 7%, and a mere
10% have comprehensive metabolic control (involving lipids, weight, blood pressure, and
blood glucose). Consequently, an adverse clinical outcome can potentially be expected when
faced with an MDRB infection[13]. This study aims to assess the relationship between
MDRB and its outcomes in IDF patients at a public hospital in Peru.

77 78

- 79 Material and Methods
- 80

81 Study Design and Setting

We conducted a retrospective cohort study on patients with DFI. We used secondary data from patients who attended the Diabetic Foot Unit (DFU) at the Maria Auxiliadora Hospital in Lima, Peru, between January 2017 and December 2019. This hospital is located in southern Lima and provides medical care to 2.5 million economically disadvantaged people. The DFU of the Endocrinology service has been the first line of treatment for IDF patients since 2015. Based on the severity, the DFU decides whether hospitalization or outpatient management is necessary.

89

90 **Patients**

91 We included patients diagnosed with IDF as per the Infectious Diseases Society of America 92 (IDSA) classification[10]. Additionally, those with a positive culture taken by the DFU staff 93 within the first 48 hours of contact were included. Patients were excluded if they had 94 extensive necrosis due to severe ischemia, no opportunity for culture, culture samples

obtained via swabs or aspiration, follow-up of less than a month if not hospitalized, infected
peripheral venous insufficiency, and pressure ulcers.

97

98 Sample Size

99 After applying the inclusion and exclusion criteria, we obtained a sample size of 192 patients.

100 The power of the sample was 88%, considering a proportion of 82% of the primary outcome

in exposed subjects, 78% in non-exposed subjects, a confidence level of 95%, and a 4:1 ratio

102 between exposed and non-exposed subjects.

103

104 Variables

105 Multidrug-Resistant Bacteria (MDRB)

MDRB was defined as a lack of susceptibility to at least one agent in three or more classes
of antimicrobials for each bacterial genus: *Staphylococcus sp., Enterococcus sp., Enterobacteriaceae, Pseudomonas sp.,* and *Acinetobacter sp.* Innate resistances to some
drugs were not considered for this definition. S1- S5 Tables. show the criteria to consider
resistance for each bacterial genus[14].

111 Adverse Clinical Outcomes

The primary composite outcome consisted of death due to IDF complications and/or major amputation (above the ankle). Secondary outcomes were death related to the diabetic foot, major amputation, minor amputation (below the ankle), hospitalization solely for medical treatment, and prolonged stay (more than 14 days).

116 Diabetic Foot Characteristics

We described the characteristics of the lesion and the patient upon admission to the DFUusing the San Elian scale. This tool includes 10 variables: description of depth, infection,

ischemia, neuropathy, location, topography, number of zones, edema, and degree of 119 120 inflammation[15]. The largest and smallest diameters of the ulcer were recorded, and the area was calculated using the ellipse formula. The degree of infection was based on the IDSA 121 122 consensus[10]. Peripheral arterial disease classification was obtained from arterial plethysmography reports, with positive results if biphasic, monophasic, or absence of wave 123 patterns were present. Peripheral neuropathy was diagnosed if there was a loss of protective 124 125 sensation evaluated with a monofilament. The glomerular filtration was calculated using the 126 CKD-EPI formula[16]. Previous exposure to antibiotics in the last year, as well as previous 127 amputation or hospitalization for diabetic foot, was documented. Furthermore, we recorded the levels of hemoglobin, albumin, leukocytes, and creatinine at the time of the acute episode. 128 We accepted HbA1c values up to one month old (S6 Table). 129

130 **Procedures**

Authorization was obtained from the Endocrinology department head to access DFU data. The endocrinology service continuously records the outcomes of its patients for administrative purposes. This spreadsheet was provided without personally identifiable information. A first request was made in February 2019 and then in December 2019. Two authors completed other data of interest by reviewing the medical records from February 2019 to January 2020 if necessary. **(S7 Table).**

137 Management Guide

The endocrinology service staff applied diagnostic and therapeutic procedures following the International Working Group of Diabetic Foot Guide for the management of infection, peripheral arterial disease, and ulcers[17]. The team consisted of four doctors and two nurses trained in comprehensive management.

142 Microbiological Analysis

The DFU staff obtained culture samples via tissue biopsy following the wound debridement
using the standard procedure[18]. The hospital laboratory staff conducted the bacterial
identification analysis and antibiotic susceptibility tests using an automated system, VITEK®
2 (BioMérieux Laboratory, Argentina)[19].

147 Statistical Analysis

Clinical and laboratory characteristics were described quantitatively, using either mean with 148 standard deviation or median with interquartile range, depending on the normality assessed 149 150 by the Shapiro-Wilk test. Categorical variables were presented with absolute and relative frequencies. Moreover, the isolated bacteria were characterized by percentages, according to 151 152 the Gram stain type and genus. To determine the differences between the groups with and without MDRB, we used the Student's T-test or U-Mann Whitney test for numerical variables 153 based on distribution. For categorical variables, we employed the Pearson's Chi-square test 154 155 or Fisher's exact test. We also assessed the incidence of the primary composite outcome based 156 on demographic and clinical characteristics.

157

158 A multivariate analysis was performed using a generalized linear model with a Poisson 159 function, logarithmic link, and robust variance to determine the relative risk (RR) for the primary and secondary outcomes. An unadjusted model and three adjusted models were 160 161 developed based on epidemiological variables. Model 1 was adjusted for age and sex, Model 2 for bone involvement, severe infection, and peripheral arterial disease, and Model 3 for 162 163 diabetes duration and HbA1C levels. The analysis was conducted using the STATA® software (version 15.1, Texas, USA), and a significance level of 5% was applied for all 164 165 hypothesis tests.

166 Ethics

167 The Institutional Ethics Committee for Research at María Auxiliadora Hospital approved the 168 development of this research project, under the code HA/CIEI/019/19. The data provided by 169 the Endocrinology Service did not contain any personally identifiable information. If it was 170 necessary to review medical records for missing data, the collection forms did not contain 171 identifying data. Only the lead author had access to the data.

172

173 **RESULTS**

The initial database comprised 582 subjects evaluated by the UPD between 2017 and 2019.
Based on eligibility criteria, we excluded 390 patients, with the primary reason for exclusion
being the absence of a bacterial culture. Ultimately, 192 patients were included in the study
(Fig 1).

178

179 Figure 1. Flowchart of patients included in the study.

180

Out of the total, 155 patients (80.8%) had a MDRB infection, 74% were males, with an average age of 59.9 ± 12.9 years. The median duration of diabetes mellitus was 12 years, the average HbA1c was 10%, and 81% of the patients had an HbA1c level of \geq 7. Notably, 28.1% of the patients developed a recurrent ulcer. As per the Wagner classification of DFI, 50.5% were classified as grade IV, and 88% had a moderate to severe infection according to the IDSA guidelines. The remaining demographic and clinical characteristics of the patients are shown in **Table 1**.

188

189

190 Table 1. Clinical and demographic characteristics according to the MDR organism.

MDRB (+)	MDRB (-)	Total	n valua
n(%)	n(%)	n(%)	p-value
155 (80.8)	37 (19.3)	192 (100)	
112 (72.3)	30 (81.1)	142 (74.0)	0.27
60.8 ± 12.9	56.5 ± 12.8	59.9 ± 12.9	0.07
83 (53.6)	13 (35.1)	96 (50.0)	0.04
12 (9 to 20)	12 (8 to 17)	12 (8 to 20)	0.72
44 (28.4)	10 (27.0)	54 (28.1)	0.87
15 (6 to 32)	18 (6 to 24)	15 (6 to 30)	0.83
4 (2.6)	1 (2.7)	5 (2.6)	0.15
12 (7.7)	6 (16.2)	18 (9.4)	
55 (35.5)	17 (46.0)	72 (37.5)	
84 (54.2)	13 (35.1)	97 (50.5)	
15 (9.7)	8 (21.6)	23 (12.0)	0.08
104 (67.1)	18 (48.6)	122 (63.5)	
36 (23.2)	11 (29.7)	47 (24.5)	
62 (40.0)	9 (24.3)	71 (37.0)	0.07
151 (97.4)	35 (94.6)	186 (96.9)	0.37
18.6±3.0	18.4±3.4	18.5 ± 3.0	0.68
58 (37.4)	12 (32.4)	70 (36.5)	0.57
12 (7.7)	2 (5.4)	14 (7.3)	0.87
55 (35.7)	11 (29.7)	66 (34.6)	0.49
32 (20.7)	4 (10.8)	36 (18.8)	0.17
52 (33.6)	16 (43.2)	68 (35.4)	0.27
	MDRB (+) $n(%)$ 155 (80.8)112 (72.3) 60.8 ± 12.9 83 (53.6)12 (9 to 20)44 (28.4)15 (6 to 32)4 (2.6)12 (7.7)55 (35.5)84 (54.2)15 (9.7)104 (67.1)36 (23.2)62 (40.0)151 (97.4)18.6 \pm 3.058 (37.4)12 (7.7)55 (35.7)32 (20.7)52 (33.6)	MDRB (+)MDRB (-) $n(%)$ $n(%)$ 155 (80.8) $37 (19.3)$ 112 (72.3) $30 (81.1)$ 60.8 ± 12.9 56.5 ± 12.8 $83 (53.6)$ $13 (35.1)$ 12 (9 to 20)12 (8 to 17)44 (28.4) $10 (27.0)$ 15 (6 to 32)18 (6 to 24)4 (2.6) $1 (2.7)$ 12 (7.7) $6 (16.2)$ 55 (35.5)17 (46.0)84 (54.2)13 (35.1)15 (9.7) $8 (21.6)$ 104 (67.1)18 (48.6)36 (23.2)11 (29.7)62 (40.0)9 (24.3)151 (97.4)35 (94.6)18.6 \pm 3.018.4 \pm 3.458 (37.4)12 (32.4)12 (7.7)2 (5.4)55 (35.7)11 (29.7)32 (20.7)4 (10.8)52 (33.6)16 (43.2)	MDRB (+)MDRB (-)Total $n(%)$ $n(\%)$ $n(\%)$ 155 (80.8)37 (19.3)192 (100)112 (72.3)30 (81.1)142 (74.0) 60.8 ± 12.9 56.5 ± 12.8 59.9 ± 12.9 83 (53.6)13 (35.1)96 (50.0)12 (9 to 20)12 (8 to 17)12 (8 to 20)44 (28.4)10 (27.0)54 (28.1)15 (6 to 32)18 (6 to 24)15 (6 to 30)4 (2.6)1 (2.7)5 (2.6)12 (7.7)6 (16.2)18 (9.4)55 (35.5)17 (46.0)72 (37.5)84 (54.2)13 (35.1)97 (50.5)15 (9.7)8 (21.6)23 (12.0)104 (67.1)18 (48.6)122 (63.5)36 (23.2)11 (29.7)47 (24.5)62 (40.0)9 (24.3)71 (37.0)151 (97.4)35 (94.6)186 (96.9)18.6 \pm 3.018.4 \pm 3.418.5 \pm 3.058 (37.4)12 (32.4)70 (36.5)12 (7.7)2 (5.4)14 (7.3)55 (35.7)11 (29.7)66 (34.6)32 (20.7)4 (10.8)36 (18.8)52 (33.6)16 (43.2)68 (35.4)

Previous diabetic foot infection	53 (34.2)	9 (24.3)	62 (32.3)	0.25
GFR , mean \pm SD	87.2 ± 32.0	95.1 ± 29.8	88.7 ± 32	0.18
Laboratory Findings				
Hemoglobin (g/dL), mean \pm SD	10.6 ± 2.0	11.0 ± 1.8	10.7 ± 1.9	0.11
Leukocytes (cells x10 ³ /mm ³), Med (IQR)	11.9 (8.4 to 16.6)	11.5 (8.4 to 16.9)	11.9 (8.4 to 16.6)	0.98
Albumin (g/dL), mean \pm SD	3.0 ± 0.6	3.2 ± 0.6	3.0 ± 0.6	0.14
HbA1c (%), mean ± SD	9.7 ± 2.9	11.7 ± 2.9	10.1 ± 3.0	0.006
$HbA1c \ge 7\%$	97 (77.6)	31 (93.9)	128 (81.0)	0.03
Microbiological				
Polymicrobial	33 (21.3)	4 (10.8)	37 (19.3)	0.14
Time				
Until last consultation (days)	172 [54 to 448]	137 [89 to 397]	163 [56.5 to 439]	
Internment	23.5 [15 to 32]	17.5 [12 to 31]	22 [15 to 32]	

192 Data are presented as n (%). DM: Diabetes Mellitus. SD: Standard Deviation. Med: Median.

193 IQR: Interquartile Range. GFR: Glomerular Filtration Rate by CKD-EPI. IDSA: Infectious194 Disease Society American.

195

Of a total of 236 isolated bacteria, 82% were MDR. The most common MDR bacteria were *Enterobacteriaceae* (51.3%), *Staphylococcus aureus* (28.4%), and *Enterococcus sp.* (8.9%).
Gram-negative bacteria represented 61% of the cases, and only 37 (19.3%) had a
polymicrobial culture. A detailed description of the isolated MDR organisms is presented in **Table 2**.

202 Table 2. Microbiological profile of the isolated bacterium according to MDRB.

 Total	MDRB (+)	MDRB (-)	
n (%)	n (%)	n (%)	p-value

It is made available under a CC-BY 4.0 International license
--

General	236 (100)	194 (82)	42 (18)	
gram				
Gram-negative	143 (61)	121 (62)	22 (52)	0.23
Gram-positive	93 (39)	73 (38)	20 (48)	
Bacterium				
Enterobacteriaceae	121 (51.3)	102 (52.6)	19 (45.2)	0.01
Pseudomonas sp.	12 (5.1)	10 (5.2)	2 (4.8)	
Acinetobacter sp.	10 (4.2)	9 (4.6)	1 (2.4)	
Staphylococcus sp.	67 (28.4)	56 (28.9)	11 (26.2)	
Enterococcus sp.	21 (8.9)	16 (8.3)	5 (11.9)	
Streptococcus sp.	5 (2.1)	1 (0.5)	4 (9.5)	

- 204
- 205

The primary outcome (death and/or major amputation) occurred in 18.9% of all patients. The mortality rate was 2.1%, and major amputation was observed in 17.7%. Regarding secondary outcomes, 67% of the general population required hospitalization. Of those hospitalized, 80% had a stay longer than 14 days (**Table 3 and S1 Fig**).

210

Table 3. Clinical outcomes according to the MDRB pre-secretion.

	Total	MDRB (+)	MDRB (-)	p-value	
		n (%)	n (%)		
Composite primary outcome	38 /192 (18.9)	36/155 (23.2)	2/37 (5.4)	0.01	
(<i>n</i> =192)					
Secondary outcomes					
Mortality (n=192)	4/192 (2.1)	3/155 (1.9)	1/37 (2.7)	0.77	

Major amputation (n=188)	34/188 (17.7)	33/152 (21.7)	1/36 (2.8)	0.008
Minor amputation ^b (n=154)	82/154 (53.2)	65/119 (54.6)	17/35 (48.6)	0.53
Hospitalization ^b (n=154)	90/154 (67.0)	66/119 (55.5)	24/35 (68.6)	0.17
Long stay ^c (n=90)	66/90 (80.0)	53/68 (80.3)	13/24 (54.2)	0.013

- ^bDoes not include fatalities or major amputations. ^cOnly in hospitalized.
- 214
- The demographic characteristics associated with the primary composite outcome were age over 60 years, duration of diabetes over 10 years, ulcer area larger than 10 cm², depth of the lesion according to Wagner classification[20], infection grade according to IDSA[10], presence of peripheral arterial disease, San Elian score $\geq 20[15]$, hemoglobin <10 g/dl, albumin <3.5 g/dl, HbA1c \geq 7%, and polymicrobial culture (Table 4). Table 4. Association between primary composite outcome and population
- 221 characteristics.
- 222

	Primary	Primary	
Variable	composite	composite	n valua
variabit	outcome ^a (+)	outcome ^a (-)	<i>p</i> -value
	n (%)	n (%)	
General	38 (19.8)	154 (80.2)	
Demographic			
Male	25 (18)	117 (82)	0.20
Age > 60 years	31 (32)	65 (68)	0.001
DM duration (years) ≥ 10	32 (24)	101 (76)	0.046
Diabetic foot ulcer			
Wagner classification			
1	0 (0)	5 (100)	0.004
2	1 (6)	17 (94)	

3	8 (11)	64 (89)	
4	29 (30)	68 (70)	
IDSA infection grade			
Mild	2 (9)	21 (91)	<0.001
Moderate	17 (14)	105 (86)	
Severe	19 (40)	28 (60)	
Peripheral arterial disease	29 (41)	42 (59)	0.001
Ulcer recurrence	15 (2)	39 (72)	0.08
Area $\geq 10 \text{ cm}^2$	32 (2)	98 (75)	0.01
Diabetic neuropathy	38 (20)	148 (80)	0.21
San Elian score ≥ 20	22 (31)	48 (69)	0.002
Comorbidities			
Previous major amputation	9 (65)	5 (35)	0,000
Previous minor amputation	11 (17)	55 (83)	0.41
Previous diabetic foot hospitalization	10 (28)	26 (72)	0.18
Previous antibiotic therapy	19 (28)	49 (72)	0.03
Previous diabetic foot infection	15 (24)	47 (76)	0.29
Chronic kidney disease <60 mil/min	7 (23)	24 (77)	0.84
Laboratory Findings			
Hemoglobin < 10 g/dl	21 (32)	44 (68)	0.006
Albumin (g/dL) <3.5 g/dL	29 (33)	60 (67)	0.007
$HbA1c \ge 7\%$	20 (16)	108 (85)	0.003
Microbiological			
Polymicrobial	13 (35)	24 (65)	0.009
Multidrug resistant organism			
Staphylococcus sp. ^b	12 (23)	40 (77)	0.15
Enterococcus sp ^c	5 (31)	11 (69)	0.20
Enterobacteriaceae ^d	22 (24)	69 (76)	0.26
Pseudomonas sp ^e	2 (20)	8 (80)	0.49
Acinetobacter sp. ^f	2 (25)	6 (75)	0.57

- ^aPrimary outcome: Mortality and/or major amputation. Total of each bacterium
- 224 bn=67 cn=20 dn=108 en=12 fn=9.

226	In the crude model, for patients with MDRB, the incidence of the primary composite
227	clinical outcome increased by 3.3 times. However, when adjusted for epidemiological
228	variables, no association was evidenced in any of the three proposed models. Among the
229	secondary outcomes, only a hospital stay longer than 14 days was associated with MDRB
230	when adjusted in any of the three proposed models. The outcomes and their adjusted RR
231	can be observed in Table 5.

Table 5. Association between MDRB and adverse clinical events: crude and adjusted models.

	Model	Crude	р-	Model 1*	Adjusted	<i>p</i> -	Model	Adjusted	<i>p</i> -value	Model	Adjusted	<i>p</i> -
			value			value	2**			3***		value
	RR	95% CI		RR	95% CI		RR	95% CI		RR	95% CI	
Composite primary												
outcome ^a												
Not MDRB	1.00			1.00			1.00			1.00		
MDRB	4.29	1.08 - 17.1	0.039	3.40	0.86 - 13.4	0.081	3.28	0.99 - 10.8	0.051	3.29	0.77 – 13.9	0.105
Secondary outcomes												
Mortality												
Not MDRB	1.00			1.00								
MDRB	0.71	0.08-6.72	0.770	0.27	0.04-1.96	0.194	0.53	0.05 - 5.91	0.611	0.27	0.05 - 1.66	0.158
Major amputation												
Not MDRB	1.00			1.00			1.00			1.00		
MDRB	7.81	1.1 - 55.5	0.040	6.45	0.91 - 45.4	0.061	5.41	0.88 - 33.2	0.068	6.55	0.89 - 47.9	0.064
Minor amputation ^b												

Not MDRB	1.00			1.00			1.00			1.00		
MDRB	1.12	0.76-1.64	0.544	1.15	0.78-1.69	0.474	0.98	0.68-1.40	0.908	1.20	0.81 - 1.77	0.350
Hospitalization ^b												
Not MDRB	1.00			1.00			1.00			1.00		
MDRB	0.81	0.61-1.07	0.133	0.84	0.64-1.11	0.222	0.77	0.59 - 1.01	0.059	0.81	0.59 - 1.10	0.182
Prolonged stay ^c												
Not MDRB	1.00			1.00			1.00			1.00		
MDRB	1.49	1.06 - 2.10	0.020	1.45	1.05 - 2.02	0.026	1.46	1.06 - 2.02	0.021	1.51	1.06 - 2.14	0.021

234 ^aPrimary composite outcome: Mortality and/or major amputation. ^bDoes not include deaths or major amputation (*n*=154). ^cOnly in hospitalized *n*=90. RR: Relative risk. CI:

235 confidence interval. *Model 1: Adjusted for age and gender. **Model 2: Adjusted for bone compromise, severe infection, and peripheral arterial disease. *** Model 3: Adjusted

for diabetes duration and HbA1C.

237 **DISCUSSION**

238 Main Results

In this study, we found no association between MDRB and the primary outcome of death
related to diabetic foot and/or major amputation, but we did find an association with a
hospital stay longer than 14 days.

242

243 Comparison with other studies

244 Different studies have shown controversial results regarding the influence of MDRB on 245 the clinical course of DFI. Gupta et al.[7] and Richard et al.[21] concluded that MDRB is 246 not associated with the clinical outcome of patients with DFI. In these studies, the lack of 247 association was attributed to early aggressive treatment, antibiotic therapy adjusted to 248 microbiological findings, and the small number of patients with MDRB included. In our 249 study, after multivariate analysis, no association was defined between MDRB and a 250 higher risk of major amputation. However, Matta et al.'s systematic review did find a 251 higher prevalence of amputation in DFI with MDRB. However, these studies only 252 performed univariate analysis and considered that the higher risk of amputation in their 253 population is more attributed to the metabolic status or immunosuppression of the 254 patients^[22].

255

In our study, we observed an MDRB prevalence of 82% [9], a figure that is significantly higher compared to other countries such as France, India, China, and Turkey, where it fluctuated between 13.8 to 72.5%[22]. One notable outlier was Ethiopia, where a staggering 93% prevalence was reported[23]. This high rate of MDRB in our research might be attributable to several factors. We did not exclude patients who had received

prior antibiotic treatment, a practice known to foster the emergence of resistant bacterial
strains[21]. In addition, 20% of our patients had a history of hospitalization due to DFI,
potentially predisposing them to selective colonization by resistant pathogens[24].
Furthermore, it's essential to bear in mind that the definition of MDRB can vary across
different studies, leading to discrepancies in reported prevalence rates based on the
specific criteria employed.

267

268 The scientific literature suggests a difference in the prevalence of gram-positive or negative germs depending on the economic level. It is described that the prevalence of 269 270 gram-negative bacteria is higher in developing countries, as in the studies by Gadepalli et 271 al.[1] and Datta et al.[25]. Similarly, in our study, gram-negative bacteria were the most 272 frequent, finding an 85% bone involvement and an 80% moderate-severe infection, which 273 is related to infection by gram-negative or mixed bacteria. Also, the Enterobacteriaceae 274 family presented the highest proportion of MDRB (52.6%), followed by the 275 Staphylococcus sp. genus (28.9%), unlike the study by McDonald et al. [26], where 276 Staphylococcus sp. was the most common MDR bacteria. The similarities of our results 277 with the studies from India mentioned above[1,25], could be related to the similar degree 278 of hygiene, health education, footwear use, and geographical area related to warm 279 climates. It could also be related to the low budget that the health system invests to create 280 programs that make the management and treatment of patients with DFI more efficient.

281

Prolonged hospitalization was the only adverse clinical event associated with MDRB, a finding similar to previous studies[8,24], which could suggest nosocomial acquisition through cross-transmission via caregivers' hands[27,28]. The search for hospital care in these patients, as well as the extended stay, may be influenced by factors such as the

complexity of the procedures, the longer duration of ulcers requiring prolonged antibiotic
treatment, timely follow-up, and slow recovery of patients with MDRB[8]. Furthermore,
it is worth highlighting that 50.5% of patients had a Wagner classification of 4 and 88%
had a moderate-severe infection according to IDSA guideline, so it was expected that a
longer hospitalization would be due to the severity of their clinical condition[29].

291

292 Other factors that modify the relationship between the presence of MDRB and adverse 293 outcomes are polymicrobial culture, vascular insufficiency, anemia, and hyperglycemia. 294 Polymicrobial culture has been associated with the severity of DFI. The symbiosis 295 between two bacteria can potentiate the damage when they are individually present[30]. 296 It is also suggested that vascular insufficiency leads to tissue hypoxia and also causes a 297 decrease in antibiotic concentrations at the site[31]. Similarly, anemia is associated with 298 a decrease in the supply of oxygen to damaged tissues, leading to poor wound healing[32]. 299 Regarding the degree of glycemic control, the population was not similarly distributed in 300 both groups, which does not allow an accurate analysis of the relationship of this variable 301 with adverse outcomes. However, most patients with DFI had suboptimal glycemic 302 control (HbA1c greater than 7% in 77.6% of patients with MDRB and 93.9% of non-303 MDRB patients), with an average HbA1c above 9%. In our study, there is also a high 304 prevalence of anemia, which distorts the interpretation and influence of this variable.

305

306 Importance in public health

307 Our study revealed a high rate of MDRB, much higher than most reports worldwide. This 308 high rate could distort the impact on outcomes. Given this reality, it's critical that all health 309 facilities establish their bacteriological profile and susceptibility for DFI. This would 310 facilitate the early and effective empirical use of antibiotics according to this profile,

avoiding delays due to the use of limited utility antibiotics that could lead to infection progression. Many MDRB patients, due to intravenous treatments, require continued hospitalization, thereby increasing the intensive use of healthcare personnel. Extended stays heighten the risk of nosocomial infections, escalate direct costs, and limit the opportunity for other patients who require admission. The finding of an association with MDRB suggests an extreme need for careful biosecurity measures against crosscontamination and fomites from healthcare personnel and other patients.

318

319 Limitations and Strengths

320 The high number of patients with MDRB could have limited their influence on outcomes in our cross-sectional analysis. We needed more non-MDRB patients to achieve a close-321 322 to-1 exposed/non-exposed ratio and improve estimation precision. Another limitation is 323 the lack of cultures for anaerobic bacteria, which could have altered the distribution of 324 germs in each group (MDRB and non-MDRB) when assessing the association. 325 Additionally, our study's findings cannot be generalized to other populations due to the 326 presence of a Diabetic Foot program, which includes a multidisciplinary team that 327 standardizes treatment, performing surgical debridement within the first 48 hours, 328 contributing to the low rate of adverse DFI clinical outcomes observed.

329

Key strengths include our use of antibiotic therapy as per the IDSA guidelines and the procedures of the International Working Group of Diabetic Foot for managing peripheral arterial disease, offloading, glycemic management, and nutrition. Also noteworthy are our adherence to recommended standards for sample collection to avoid contamination and the use of a modern system for evaluating bacterial susceptibility.

335

336 Conclusion

337 Our study did not find association between MDRB and death and/or major amputation, 338 but it did with hospitalization exceeding 14 days. The high proportion of MDRB in the total sample and the cross-sectional design may have limited the discovery of differences 339 340 in the main outcome. Further prospective studies, with larger sample sizes and equivalent 341 studies, are needed to confirm its effect on these outcomes. The high prevalence of 342 MDRB highlights the need for strategies to improve the timely identification of diabetic 343 foot ulcers, as well as proper sample collection to identify pathogens and determine their 344 susceptibility pattern to antibiotics before treatment initiation.

345

346 **References**

- Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R. A clinicomicrobiological study of diabetic foot ulcers in an Indian tertiary care hospital.
 Diabetes Care. 2006;29: 1727–1732. doi:10.2337/dc06-0116
- Bansal E, Garg A, Bhatia S, Attri AK, Chander J. Spectrum of microbial flora in diabetic foot ulcers. Indian J Pathol Microbiol. 2008;51: 204–208. doi:10.4103/0377-4929.41685
- 353 3. Saravia-Hernández E, Salvador-Carrillo J, Zevallos KAV, Calderón-Ticona J. The
 andscape of diabetic foot in Peru.: Investigación Clínica. 2021;62: 276–289.
- doi:10.22209/IC.v62n3a07
- 4. Ozer B, Kalaci A, Semerci E, Duran N, Davul S, Yanat AN. Infections and aerobic
- bacterial pathogens in diabetic foot. 2010 [cited 27 May 2020]. Available:
- 358 /paper/Infections-and-aerobic-bacterial-pathogens-in-foot-Ozer-
- 359 Kalaci/415b949cf52d78bfb8b91e9b2bd18728c14958a7

5. Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to
guide antibiotic selection? Clin Microbiol Infect. 2007;13: 351–353.
doi:10.1111/j.1469-0691.2007.01697.x

363 6. Kathirvel M, Prabakaran V, Jayarajan J, Sivakumar A, Govindan V. Risk factors for
364 the diabetic foot infection with multidrug-resistant microorganisms in South India.
365 International Surgery Journal. 2018;5: 675–682. doi:10.18203/2349366 2902.isj20180374

367 7. Gupta S, Attri A, Khanna S, Chander J, Mayankjayant. Outcome in Patients of
368 Diabetic Foot Infection with Multidrug Resistant Organisms. Journal of Foot and

369 Ankle Surgery (Asia Pacific). 2018;5: 51–55. doi:10.5005/jp-journals-10040-1089

8. Hartemann-Heurtier A, Robert J, Jacqueminet S, Ha Van G, Golmard JL, Jarlier V, et

al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact.

372 Diabetic Medicine. 2004;21: 710–715. doi:10.1111/j.1464-5491.2004.01237.x

9. Richard J-L, Sotto A, Jourdan N, Combescure C, Vannereau D, Rodier M, et al. Risk

374 factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers.

375 /data/revues/12623636/00340004/08001432/. 2008 [cited 23 Apr 2020]. Available:

376 https://www.em-consulte.com/en/article/183575

377 10.Lipsky BA, Aragón-Sánchez J, Diggle M, Embil J, Kono S, Lavery L, et al. IWGDF

378 guidance on the diagnosis and management of foot infections in persons with diabetes.

379 Diabetes Metab Res Rev. 2016;32 Suppl 1: 45–74. doi:10.1002/dmrr.2699

380 11.Crouzet J, Lavigne JP, Richard JL, Sotto A, Nîmes University Hospital Working

381 Group on the Diabetic Foot (GP30). Diabetic foot infection: a critical review of recent

randomized clinical trials on antibiotic therapy. Int J Infect Dis. 2011;15: e601-610.

383 doi:10.1016/j.ijid.2011.05.003

- 384 12.Department of Surgery, Government Medical College, Kozhikode, Kerala, India,
- 385 Valappil RK. Multidrug Resistant Organisms in Diabetic Foot Ulcers-Analysis of Risk
- 386 Factors and Clinical Outcome. jmscr. 2017;05: 18138–18183.
- 387 doi:10.18535/jmscr/v5i2.144. https://doi.org/10.20453/rmh.v26i3.2584
- 388 13.Jasso-Huamán LE, Villena-Pacheco A, Guevara-Linares X. Control metabólico en
- pacientes diabéticos ambulatorios de un hospital general. 2015;26: 167-172.
- 390 14. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.
- 391 Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an
- international expert proposal for interim standard definitions for acquired resistance.
- 393 Clin Microbiol Infect. 2012;18: 268–281. doi:10.1111/j.1469-0691.2011.03570.x
- 394 15.Jesus FRM-D, Ibrahim A, Rodriguez-Ramirez N, Zambrano-Loaiza E. The latin
- american Saint Elian wound score system (sewss) for the triage of the diabetic foot
 attack. Cir Cir. 2021;89: 679–685. doi:10.24875/CIRU.20000283
- 397 16.Clinical Version: eGFR using CKD-EPI (2021 update) | QxMD. In: Calculate by
- 398QxMD[Internet].[cited17Jul2023].Available:
- 399 https://qxmd.com/calculate/calculator_251/egfr-using-ckd-epi-2021-update
- 400 17.Issue Information. Diabetes/Metabolism Research and Reviews. 2020;36: e3293.
 401 doi:10.1002/dmrr.3293
- 402 18.Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB, et al. A
- 403 Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious
- 404 Diseases: 2013 Recommendations by the Infectious Diseases Society of America
- 405 (IDSA) and the American Society for Microbiology (ASM)a. Clin Infect Dis. 2013;57:
- 406 e22–e121. doi:10.1093/cid/cit278
- 407 19.VITEK® MS Prime. In: bioMérieux Argentina [Internet]. [cited 17 Jul 2023].
- 408 Available: https://www.bmxclinicaldiagnostics-arg.com/vitek-ms-prime-arg

- 409 20.Shah P, Inturi R, Anne D, Jadhav D, Viswambharan V, Khadilkar R, et al. Wagner's
- 410 Classification as a Tool for Treating Diabetic Foot Ulcers: Our Observations at a
- 411 Suburban Teaching Hospital. Cureus. 14: e21501. doi:10.7759/cureus.21501
- 412 21.Richard J-L, Sotto A, Jourdan N, Combescure C, Vannereau D, Rodier M, et al. Risk
- 413 factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers.
- 414 Diabetes Metab. 2008;34: 363–369. doi:10.1016/j.diabet.2008.02.005
- 415 22.Matta-Gutiérrez G, García-Morales E, García-Álvarez Y, Álvaro-Afonso FJ, Molines-
- 416 Barroso RJ, Lázaro-Martínez JL. The Influence of Multidrug-Resistant Bacteria on
- 417 Clinical Outcomes of Diabetic Foot Ulcers: A Systematic Review. J Clin Med.
- 418 2021;10: 1948. doi:10.3390/jcm10091948
- 419 23.Atlaw A, Kebede HB, Abdela AA, Woldeamanuel Y. Bacterial isolates from diabetic
- 420 foot ulcers and their antimicrobial resistance profile from selected hospitals in Addis
- 421 Ababa, Ethiopia. Frontiers in Endocrinology. 2022;13. Available:
- 422 https://www.frontiersin.org/articles/10.3389/fendo.2022.987487
- 423 24.Zubair M, Malik A, Ahmad J. Clinico-bacteriology and risk factors for the diabetic
- 424 foot infection with multidrug resistant microorganisms in north India. Biology and
 425 Medicine. 2010;2: 0–0.
- 426 25.Datta P, Chander J, Gupta V, Mohi GK, Attri AK. Evaluation of various risk factors
 427 associated with multidrug-resistant organisms isolated from diabetic foot ulcer
- 428 patients. J Lab Physicians. 2019;11: 58–62. doi:10.4103/JLP.JLP_106_18
- 429 26.Macdonald KE, Boeckh S, Stacey HJ, Jones JD. The microbiology of diabetic foot
- 430 infections: a meta-analysis. BMC Infect Dis. 2021;21: 770. doi:10.1186/s12879-021-
- 431 06516-7
- 432 27.Murali TS, Kavitha S, Spoorthi J, Bhat DV, Prasad ASB, Upton Z, et al.
- 433 Characteristics of microbial drug resistance and its correlates in chronic diabetic foot

434 ulcer infections. J Med Microbiol. 2014;63: 1377–1385. doi:10.1099/jmm.0.076034-

435 0

- 436 28.Islam S, Cawich SO, Budhooram S, Harnarayan P, Mahabir V, Ramsewak S, et al.
- 437 Microbial profile of diabetic foot infections in Trinidad and Tobago. Prim Care
- 438 Diabetes. 2013;7: 303–308. doi:10.1016/j.pcd.2013.05.001
- 439 29. Choi SK, Kim CK, Jo DI, Lee MC, Kim JN, Choi HG, et al. Factors Associated with
- 440 a Prolonged Length of Hospital Stay in Patients with Diabetic Foot: A Single-Center
- 441 Retrospective Study. Arch Plast Surg. 2017;44: 539–544. doi:10.5999/aps.2017.01207
- 442 30.Hitam SAS, Hassan SA, Maning N. The Significant Association between
- 443 Polymicrobial Diabetic Foot Infection and Its Severity and Outcomes. Malays J Med
- 444 Sci. 2019;26: 107–114. doi:10.21315/mjms2019.26.1.10
- 445 31. Aysert Yıldız P, Özdil T, Dizbay M, Güzel Tunçcan Ö, Hızel K. Peripheral arterial
- disease increases the risk of multidrug-resistant bacteria and amputation in diabetic
- 447 foot infections. Turk J Med Sci. 2018;48: 845–850. doi:10.3906/sag-1803-217
- 448 32.Salman I, AL-Shammaree S, Abualkasem B. Low Hemoglobin Levels in Infected
- 449 Diabetic Foot Ulcer. IOSR Journal of Pharmacy and Biological Sciences. 2017;12:
- 450 05–09. doi:10.9790/3008-1201040509

Supporting information 452

- 453 S1 Fig. Diagram of distribution of outcomes in the study's patients.
- 454 S1 Table. Categories and agents used to define *Staphylococcus aureus* MDR, XDR,
- 455 and PDR.
- 456 S2 Table. Categories and agents used to define Enterococcus sp MDR, XDR and
- 457 PDR.
- S3 Table. Categories and agents used to define Enterobacteriaceae MDR, XDR and 458
- PDR. 459
- 460 S4 Table. Categories and agents used to define Pseudomonas aeuruginosa MDR,
- 461 **XDR and PDR.**
- 462 S5 Table. Categories and agents used to define Acinetobacter spp MDR, XDR and
- PDR. 463
- S6 Table. Scales used in the study to assess the characteristics of the DFI. 464
- S7 Table. Data collection instrument. 465



Figure 1